The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(1-methyl-1H-pyrazol-3-yl)phenyl)amino)-N-methylnicotinamide ID: ALA4566158
Chembl Id: CHEMBL4566158
PubChem CID: 90153821
Max Phase: Preclinical
Molecular Formula: C24H24FN7O2
Molecular Weight: 461.50
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: CNC(=O)c1cnc(Nc2cc(C)c(F)cn2)cc1Nc1cccc(-c2ccn(C)n2)c1OC
Standard InChI: InChI=1S/C24H24FN7O2/c1-14-10-21(28-13-17(14)25)30-22-11-20(16(12-27-22)24(33)26-2)29-19-7-5-6-15(23(19)34-4)18-8-9-32(3)31-18/h5-13H,1-4H3,(H,26,33)(H2,27,28,29,30)
Standard InChI Key: RVVNUPVNYWTCKJ-UHFFFAOYSA-N
Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 461.50Molecular Weight (Monoisotopic): 461.1976AlogP: 4.18#Rotatable Bonds: 7Polar Surface Area: 105.99Molecular Species: NEUTRALHBA: 8HBD: 3#RO5 Violations: ┄HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: 13.20CX Basic pKa: 5.91CX LogP: 4.94CX LogD: 4.93Aromatic Rings: 4Heavy Atoms: 34QED Weighted: 0.38Np Likeness Score: -1.32
References 1. Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L, Shuster D, Gillooly K, Yang X, Heimrich E, McIntyre KW, Chaudhry C, Khan J, Ruzanov M, Tredup J, Mulligan D, Xie D, Sun H, Huang C, D'Arienzo C, Aranibar N, Chiney M, Chimalakonda A, Pitts WJ, Lombardo L, Carter PH, Burke JR, Weinstein DS.. (2019) Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165., 62 (20): [PMID:31318208 ] [10.1021/acs.jmedchem.9b00444 ]